Efficiency and tolerance of immunotherapy in the treatment of cancer patients living with HIV

The French CANCERVIH network, coordinated by Prof. Jean-Philippe Spano of the Medical Oncology Department of the Pitié-Salpêtrière Hospital AP-HP and Sorbonne University, studied the efficacy and safety of immunotherapy on the world’s largest series of HIV-infected people with cancer treated in routine care (excluding clinical trials).

The results, which show that the treatment is effective and well tolerated, represent a real advance in the management of HIV-infected patients with cancer.  They were published on 26 June 2019 in the journal AIDS.

More information : https://www.aphp.fr/contenu/efficacite-et-tolerance-de-limmunotherapie-dans-le-traitement-de-patients-atteints-de-cancer


Sources : 

Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.

Spano JP1, Veyri M2, Gobert A3, Guihot A4, Perré P5, Kerjouan M6, Brosseau S7, Cloarec N8, Montaudie H9, Helissey C10, Flament T11, Gounant V7, Lavolé A12, Poizot-Martin I13, Katlama C14.

AIDS. 2019 Jun 26. doi: 10.1097/QAD.0000000000002298.